RNAC (Cartesian Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RNAC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | Murat Kalayoglu | 10%+ Owner | M | — | — |
| 2026-04-06 | Seven One Eight Three Four Irrevocable Trust | 10%+ Owner | M | — | — |
| 2026-03-13 | Michael Singer | Director | G | — | — |
| 2026-01-08 | Milos Miljkovic | Chief Medical Officer | Sell | — | — |
| 2026-01-08 | Carsten Brunn | President and CEO | Sell | — | — |
| 2026-01-08 | Blaine Davis | Chief Financial Officer | Sell | — | — |
| 2026-01-06 | June Ann Seymour | Chief Accounting Officer | A | — | — |
| 2026-01-06 | Emily English | Chief Operations Officer | A | — | — |
| 2026-01-06 | Blaine Davis | Chief Financial Officer | A | — | — |
| 2026-01-06 | Kemal Malik | Director | A | — | — |
| 2026-01-06 | TIMOTHY C BARABE | Director | A | — | — |
| 2026-01-06 | Carsten Brunn | President and CEO | A | — | — |
| 2026-01-06 | Nishan M DeSilva | Director | A | — | — |
| 2026-01-06 | Milos Miljkovic | Chief Medical Officer | A | — | — |
| 2026-01-06 | PATRICK J ZENNER | Director | A | — | — |
| 2026-01-06 | Murat Kalayoglu | Director | A | — | — |
| 2026-01-06 | TIMOTHY A SPRINGER | Director | A | — | — |
| 2026-01-06 | Michael Singer | Director | A | — | — |
| 2026-01-02 | Emily English | Chief Operations Officer | M | — | — |
| 2025-12-18 | Adrian Ion Bot | Director | A | — | — |
| 2025-12-08 | TIMOTHY C BARABE | Director | Buy | — | — |
| 2025-12-02 | Emily English | Chief Operations Officer | M | — | — |
| 2025-11-19 | Michael Singer | Director | G | — | — |
| 2025-10-28 | June Ann Seymour | Chief Accounting Officer | A | — | — |
| 2025-05-14 | Emily English | Chief Operations Officer | M | — | — |
| 2025-04-16 | Emily English | Chief Operations Officer | M | — | — |
| 2025-04-11 | TIMOTHY A SPRINGER | Director | Buy | — | — |
| 2025-03-20 | TIMOTHY A SPRINGER | Director | Buy | — | — |
| 2025-01-15 | TIMOTHY A SPRINGER | Director | Buy | — | — |
| 2025-01-13 | Christopher M Jewell | Chief Scientific Officer | M | — | — |
| 2025-01-07 | Blaine Davis | Chief Financial Officer | Sell | — | — |
| 2025-01-07 | Milos Miljkovic | Chief Medical Officer | Sell | — | — |
| 2025-01-07 | Emily English | Chief Operations Officer | Sell | — | — |
| 2025-01-07 | Christopher M Jewell | Chief Scientific Officer | Sell | — | — |
| 2025-01-07 | Metin Kurtoglu | Chief Technology Officer | Sell | — | — |
| 2025-01-07 | Carsten Brunn | President and CEO | Sell | — | — |
| 2025-01-06 | Nishan M DeSilva | Director | A | — | — |
| 2025-01-06 | TIMOTHY A SPRINGER | Director | A | — | — |
| 2025-01-06 | Milos Miljkovic | Chief Medical Officer | A | — | — |
| 2025-01-06 | TIMOTHY C BARABE | Director | A | — | — |
| 2025-01-06 | Christopher M Jewell | Chief Scientific Officer | A | — | — |
| 2025-01-06 | Murat Kalayoglu | Director | A | — | — |
| 2025-01-06 | Kemal Malik | Director | A | — | — |
| 2025-01-06 | Emily English | Chief Operations Officer | A | — | — |
| 2025-01-06 | Carsten Brunn | President and CEO | A | — | — |
| 2025-01-06 | Blaine Davis | Chief Financial Officer | A | — | — |
| 2025-01-06 | PATRICK J ZENNER | Director | A | — | — |
| 2025-01-06 | CARRIE SMITH COX | Director | A | — | — |
| 2025-01-06 | Michael Singer | Director | A | — | — |
| 2025-01-06 | Metin Kurtoglu | Chief Technology Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 9,302,798 | — |
| — | Director | 5,820,260 | — |
| — | 10%+ Owner | 506,999 | — |
| — | President and CEO | 323,530 | — |
| — | Director | 145,797 | — |
| — | Chief Financial Officer | 121,220 | — |
| — | Chief Operations Officer | 94,226 | — |
| — | Chief Scientific Officer | 62,490 | — |
| — | Chief Technology Officer | 62,258 | — |
| — | Chief Medical Officer | 58,820 | — |
| — | Director | 56,966 | — |
| — | Director | 15,629 | — |
| — | Director | 12,974 | — |
| — | Director | 11,366 | — |
| — | Director | 11,133 | — |
| — | Chief Accounting Officer | 6,500 | — |
| — | Director | 5,933 | — |
| — | Director | 5,800 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RNAC quote page; the site-wide leaderboard is on the insider transactions hub.